Condition

Gastric or Gastroesophageal Junction Adenocarcinoma

ClinicalTrials.gov condition label

Clinical trials3

Recruiting0

Common interventions5

Lead sponsors shown1

Clinical trials

3 shown

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsNCT03849469 · 2019-05-29

COMPLETED

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)NCT03752398 · 2019-05-01

COMPLETED

A Study of XmAb®20717 in Subjects With Selected Advanced Solid TumorsNCT03517488 · 2018-07-10

COMPLETED

Common interventions

Pembrolizumab (Keytruda®)BIOLOGICAL1XmAb®22841BIOLOGICAL1XmAb®23104BIOLOGICAL1XmAb20717BIOLOGICAL1Yervoy® (ipilimumab)BIOLOGICAL1

Leading sponsors

Xencor, Inc.3

Trial status mix

COMPLETED3

Phase mix

PHASE13

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.